Navigation Links
Transition in cell type parallels treatment response, disease progression in breast cancer
Date:1/31/2013

A process that normally occurs in developing embryos the changing of one basic cell type into another has also been suspected of playing a role in cancer metastasis. Now a study from Massachusetts General Hospital (MGH) Cancer Center researchers has associated this process, called epithelial-mesenchymal transition or EMT, with disease progression and treatment response in breast cancer patients. The report also identifies underlying mechanisms that someday may become therapeutic targets.

"Until now, EMT had only been modeled in experimental systems, but its clinical relevance was uncertain. Now we show that it can be detected in samples from breast cancer patients and that the tumor cells oscillate between these two states" says Shyamala Maheswaran, PhD, of the MGH Cancer Center, co-corresponding author of the report in the Feb. 1 issue of Science. "We find that the EMT state of breast cancer cells evolves in response to therapy and to disease recurrence, pointing to involvement of this mechanism in tumor spread and invasiveness."

Epithelial tissues line most bodily surfaces and cavities, and epithelial cells closely adhere to each other. During development, some epithelial cells develop traits of mesenchymal cells, including the ability to migrate to other parts of the embryo, establish themselves and develop into organs or other types of tissue. Several studies have suggested that a transition from epithelial to mesenchymal cell type is also involved with cancer metastasis, which involves tumor cells' migration to and invasion of other sites in the body, but identifying EMT stages of tissues has been challenging.

The MGH investigators developed a new assay that determines EMT stage by screening tumor samples for seven epithelial markers and three mesenchymal markers. In primary tumor samples from several breast cancer patients including samples of estrogen-receptor/progesterone-receptor-positive, HER2-positive
'/>"/>

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Topological transitions in metamaterials
2. Study Shows Transition to Practice Programs Get Nurses Employed
3. Innosight Announces Leadership Transition
4. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
5. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
6. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
7. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
8. Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union
9. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
10. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
11. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)...  Heidrick & Struggles (Nasdaq: HSII ), the premier ... and culture shaping worldwide, today  announced that ... global Healthcare and Life Sciences practice. As Global ... lead a team of more than 80 partners, principals and ... Asia serving clients in the biopharmaceutical, ...
(Date:3/30/2015)... OTTAWA , March 30, 2015 /CNW/ - A ... today on the salaries and demographic profiles of new ... "Opening the Door – Building Careers for New Grads ... Canada,s Research-Based Pharmaceutical Companies (Rx&D) and features ... federal Career Focus wage subsidy program from 2013 to ...
(Date:3/30/2015)... , March 30, 2015  Naldemedine, an ... development by Shionogi & Co., Ltd., met its ... study (COMPOSE I) for the treatment of opioid-induced ... pain receiving opioid therapy. Study results showed that ... significantly improved the frequency of spontaneous bowel movement ...
(Date:3/29/2015)... , March 29, 2015 ... of important study data showing the presence ... 1,599 gynecologic cancer samples. Using Caris Molecular ... service, researchers identified expression of programmed cell ... independent of histology while its ligand (PD-L1) ...
Breaking Biology Technology:Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4
... Va., May 7 Champions,Biotechnology, Inc. (OTC ... the,development of advanced preclinical platforms and tumor ... drugs, today announced that it has,established an ... evaluation of certain therapeutic antibodies in ImClone,s,clinical ...
... Cohera Medical, Inc., a rapidly,growing medical device company ... adhesives, announced today that it has closed an,insider ... proceeds of this,transaction will support the growth of ... product, TissuGlu(R), a strong, resorbable surgical,adhesive, as well ...
... NOVATO, Calif., May 7 BioMarin Pharmaceutical,Inc. (Nasdaq and ... of BioMarin, will present a company update at the,Bank ... May 14,2008 at 1:20 p.m. PT., Interested parties ... the investor section of the BioMarin website, http://www.BMRN.com ...
Cached Biology Technology:Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs 2Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs 3Cohera Medical, Inc. Announces Closing of Insider Round of Financing for Over $7.6 Million 2BioMarin to Present at the Bank of America Healthcare Conference 2
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has ... Global Strategic Business Report" report to their offering. ... in US$ Thousands by the following Segments: Face Biometrics, and Voice ... Canada , Japan , ... East & Africa , and ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... Bartness, Regents, Professor of Biology at Georgia State University, ... Institutes of Health to further research into the biological ... Research in Time (MERIT) award from the National Institute ... his lab,s investigation into the communication loop between fat ...
... new study suggests that it might be a genetic ... three thousand men - all pairs of male twins ... first time they had sex. Many participants in the ... and premature ejaculation at their first sexual encounter. These ...
... called a "Dream Team." Lombardi Comprehensive Cancer ... DSc, and 12 of the nation,s top breast cancer ... Stand Up To Cancer (SU2C) to form a scientific ... and brightest scientists will conduct new breast cancer research ...
Cached Biology News:Researcher garners major award from NIH for further exploration into the mechanisms of obesity 2Lombardi scientist brings 'dream team' breast cancer research effort to GUMC 2Lombardi scientist brings 'dream team' breast cancer research effort to GUMC 3
ANTI DEOXY CORTICO...
... Automatic High Sensitivity Laboratory Osmometer for both 0.2 and 2.0 mL samples for ... and record keeping. Bar code reading capability with optional scanner. RS-232 port. ... ... ...
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20*...
sodium channel, nonvoltage-gated 1 alpha,...
Biology Products: